scholarly journals Necrotizing autoimmune myopathy with tubular aggregates

Neurology ◽  
2019 ◽  
Vol 93 (7) ◽  
pp. 313-314
Author(s):  
Nicolas N. Madigan ◽  
Teerin Liewluck ◽  
Margherita Milone ◽  
Elie Naddaf
2021 ◽  
pp. 247412642199860
Author(s):  
Jonathan Cin-Bon Tsui ◽  
Gordon Scott Crabtree

Purpose: This work reports a case of combined vascular occlusion in the setting of intravenous immunoglobulin (IVIg) administration. Methods: The authors describe a case of combined central retinal vein and cilioretinal artery that occurred in the setting of IVIg administration. Results: A 52-year-old White man presented with a unilateral subjective scotoma that began during IVIg administered for the treatment of statin-induced necrotizing autoimmune myopathy. Examination and optical coherence tomography imaging revealed a combined nonischemic central retinal vein and cilioretinal artery occlusion. Conclusions: To the authors’ review and knowledge, this is the first reported case of combined central retinal vein and cilioretinal artery occlusion occurring in the setting of IVIg administration. This rare adverse effect is an entity to be considered in patients who are treated with IVIg.


2011 ◽  
Vol 23 (6) ◽  
pp. 612-619 ◽  
Author(s):  
Christina Liang ◽  
Merrilee Needham

2021 ◽  
Vol 5 (6) ◽  
Author(s):  
Kyunghee Lim ◽  
Jong Sung Park ◽  
Byeol-A Yoon ◽  
Song-Hee Han

Abstract Background Necrotizing autoimmune myopathy is a rare subtype of idiopathic inflammatory myopathy; however, it can be associated with fatal cardiac manifestations. Case summary A 58-year-old female patient was referred for congestive heart failure with dysrhythmia. Electrocardiograms showed ventricular arrhythmias of various QRS complex morphologies and coupling intervals with beat-to-beat differences. Despite optimal medical therapy for heart failure, the patient was admitted for the progression of dyspnoea and generalized motor weakness. The burden of non-sustained ventricular tachycardia gradually increased, and ventricular fibrillation eventually occurred. In view of a differential diagnosis of an inflammatory myocardial diseases such as sarcoidosis, a cardiac biopsy was performed. However, pathologic examinations revealed only necrotic muscle fibres without granuloma. Further examinations revealed proximal dominant motor weakness, an elevated serum creatinine-phosphokinase level, myogenic potentials on needle electromyography, and biceps muscle biopsy findings that were compatible with necrotizing autoimmune myopathy. High-dose steroid therapy improved the patient’s motor weakness, including her respiratory impairment, and successfully suppressed ventricular arrhythmias. Discussion This case suggests that intensive immunosuppressive therapy with high-dose steroid could be useful in the necrotizing autoimmune myopathy manifested as congestive heart failure and life-threatening ventricular arrhythmias.


2020 ◽  
Vol 6 (2) ◽  
pp. e86-e89
Author(s):  
Shirley Shuster ◽  
Sara Awad

Objective: Necrotizing autoimmune myopathy (NAM) is a rare side-effect of statin therapy. We report the case of a patient who developed statin-induced NAM with a review of the clinical presentation and management of this rare entity. The case illustrates the importance of including NAM in the differential diagnosis of persistent myopathy in a statin-exposed individual. Methods: A 74-year-old male was referred to endocrinology for hypercholesterolemia management in the context of a statin contraindication. He previously developed myositis and rhabdomyolysis secondary to statin therapy, but continued to have persistent proximal lower limb muscle weakness despite statin discontinuation. Rheumatologic and metabolic work-up were negative and neurologic work-up was negative except for a myopathic pattern in the glutei found on electromyography. Results: Due to the persistence of proximal myopathy despite statin discontinuation and myopathic pattern seen on electromyography, NAM was suspected and antibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase were sent and came back positive. The patient was treated with the immunosuppressant azathioprine, which resulted in clinical improvement. The patient was started on a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolucumab for hypercholesterolemia, which resulted in significant improvement in his lipid panel. Conclusion: The case illustrates the presentation and management of statin-induced NAM. We demonstrate the necessity for prompt diagnosis and timely management, as statin therapy is contraindicated and immunosuppressive therapy is warranted. Statin-induced NAM is rare however, it should be included in the differential diagnosis of persistent myopathy despite statin discontinuation. PCSK9 inhibitors are the only alternative therapy for hypercholesterolemia management in patients with statin-induced NAM.


2015 ◽  
Vol 72 (9) ◽  
pp. 996 ◽  
Author(s):  
Charles D. Kassardjian ◽  
Vanda A. Lennon ◽  
Nora B. Alfugham ◽  
Michael Mahler ◽  
Margherita Milone

2019 ◽  
Vol 31 (4) ◽  
pp. 269-272 ◽  
Author(s):  
Yehia Saleh ◽  
Khader Herzallah ◽  
Mohamed Hassanein ◽  
Howard T. Chang

2013 ◽  
Vol 23 (9-10) ◽  
pp. 816
Author(s):  
B. Jaeger ◽  
M. de Visser ◽  
E. Aronica ◽  
A.J. van der Kooi

2015 ◽  
Vol 30 (12) ◽  
pp. 1879-1883 ◽  
Author(s):  
Laura Nichols ◽  
Kurt Pfeifer ◽  
Andrew L. Mammen ◽  
Nazima Shahnoor ◽  
Chamindra G. Konersman

Sign in / Sign up

Export Citation Format

Share Document